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Contributors: L. SENTERFIT, New York: Mechanisms of Action of Antibiotics
D. TAYLOR-ROBINSON, Middlesex: Methods for Testing the
Antibiotic Sensitivity of Mycoplasma
Y. NIITU, Sendai: Antibiotic Resistance: Occurrence and
Mechanisms
G. LABER, Vienna: Non-Antibiotic Chemicals (povidone-iodine,
etc.)
R. McCOY, Fort Lauderdale: Antibiotics in Plant Diseases
T.A. CHEN, New Brunswick: Antimycoplasmal Substances in
Plants
K. JURMANOVA, Brno: Antibiotics and Cell Cultures
D. Taylor-Robinson stated that the principles of testing antibiotics for anti-
mycoplasmal activity are similar to those of testing antibodies. Thus, the methods
used are inhibition of colony formation on agar and inhibition of a color change in
liquid medium; that is, the metabolism-inhibition (MI) test. The latter may be per-
formed in vials or microtiter plates. Care must be taken to ensure that the plates and
loops are not toxic to the mycoplasmas and, therefore, causing spurious results. The
results of MI tests may be recorded when color changes are first seen in the control
wells (initial inhibitory concentration) and when color changes no longer occur on
continued incubation (final inhibitory concentration). The latter concentration is
almost always more than the former. The extent to which an antibiotic kills myco-
plasmas is determined by withdrawing a sample from the antibiotic-mycoplasma
mixture after an indicated time. The sample is diluted to the point where the an-
tibiotic can not be inhibitory and is then cultured, or it is filtered to trap the myco-
plasmas and the filter, after washing, is cultured.
Y. Niitu described how two pediatric patients with M. pneumoniae pneumonia
were treated with erythromycin or josamycin. The isolates before therapy were sen-
sitive to erythromycin or josamycin, whereas the later isolates had acquired a high
degree of resistance to erythromycin or josamycin. The results revealed that M.
pneumoniae can acquire resistance to erythromycin or josamycin in vivo. He could
make M. pneumoniae resistant to every macrolide by inoculating M. pneumoniae
into agar media containing the macrolide. The resistance developed to one macrolide
in vitro or in vivo was accompanied by cross-resistance to other macrolides and
analogues. He could also make M. pneumoniae resistant to streptomycin and
chloramphenicol in vitro, but not to tetracycline.
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The antibiotic sensitivity was compared among isolates recovered before and after
or during the administration of an antibiotic over seven days. Resistance developed
to erythromycin in three of 39 patients, to josamycin in four of 18, to chlorampheni-
col in none of 13, and to the tetracycline group in none of 16.
The antibiotic sensitivity was tested in 505 M. pneumoniae isolates first recovered
from the same number of patients from 1965 through 1981. Erythromycin resistance
was observed in three isolates. The resistance was assumed not to be primary
resistance but to have developed by the administration of erythromycin which all
three patients had received prior to isolation. A high degree of streptomycin resis-
tance was observed in 3 percent of 370 isolates before 1979 but thereafter in none of
135 isolates. At present wedo not need to consider the infection with M. pneumoniae
primarily resistant to antibiotics, but must carefully watch the problem in the future.
To study the mechanism of the development of resistance, FH strain and three
isolates of M. pneumoniae were inoculated on agar media with various concentra-
tions of erythromcyin. One or a few colonies were grown at lower and higher con-
centrations. All the colonies showed high values in the MIC of erythromycin. The
resistance to macrolides may develop by the selection of the high-resistant variant by
the drug.
With tetracycline, higher concentrations permitted no growth. This may be the
reason why tetracycline-resistant M. pneumoniae was neither made in vitro nor
isolated in vivo.
G. Laber discussed why knowledge about the efficacy of disinfectants against
various mycoplasma species can be important for several reasons. The main aspects
are as follows: (1) Hygienic Aspects: (a) Disinfection as an important preventive ac-
tivity in the defense of mycoplasma-caused diseases in animals and (b) Disinfection
of medical instruments to reduce or hinder the possibility of transfer of infection be-
tween patients or animals; (2) Treatment Aspects: Use of locally non-irritating com-
pounds to lower or eliminate mycoplasma species (especially antibiotic-resistant)
from mucous surfaces; (3) Microbiological Aspects: Achievement of optimum con-
ditions for isolation of mycoplasmas from specimens containing disinfectants;
(4) Safety Aspects: Recommendations for protection of laboratory staff or persons
who are handling specimens or cultures of mycoplasma (personal protection) or les-
sening the risk of contamination of laboratory equipment.
Principally, mycoplasma species are moderately to highly sensitive to disinfec-
tants, probably because they lack a rigid cell wall or elements like slime which mostly
serve as a barrier for penetration.
There is a ranking within the range of sensitivity of various mycoplasma species
against different disinfectants, depending upon in vitro or in vivo conditions, the
test system, the chemical compound, and the time of exposure used.
In one study it was stressed that povidone iodine displayed several advantages in
being water-soluble, fairly stable, non-staining, and easy to prepare and in having a
pronounced killing effect on ureaplasma and mycoplasma (M. hominis) in vitro.
Killing occurred at a concentration of 0.6 percent, latest within five minutes. As
hypersensitivity to iodine can occur, preparations containing chlorhexidine or cer-
rimide could be useful.
For disinfection surfaces in laboratories, preparations containing phenol, for-
maldehyde, or alcohols are suitable.
For testing the activity of disinfectants against mycoplasmas, the suspension
method and carrier method are used.
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Problems in the test or use of disinfectants to mycoplasmas are as follows:
(1) Serum contained in media might interfere with results of a sensitivity test; (2) A
neutralizer system has to be investigated; (3) A standardization ofthe assay methods
for sensitivity of mycoplasmas to disinfectants is still lacking; (4) A prerequisite for
the use of disinfectants in veterinary medicine is intensive cleaning.
R. McCoy stated that the first reports of the association of mycoplasma-like
organisms with plant disease came from Doi and co-workers in Japan in 1967. Cor-
roborative evidence was presented by Ishii et al., when they demonstrated that
dwarfed diseased mulberry would respond to applications oftetracycline antibiotics.
Since that time tetracycline has been used as a diagnostic aid in determining the
possible role of mycoplasmas in plant disease. In addition, tetracycline has been
registered in several countries for the control of several diseases of tree crops.
Treatment of trees is done by injection and the effect of treatment lasts four
months to a year or more. Such treatment limits the environmental exposure of the
antibiotic, and the long duration of remission helps to reduce the costs of applica-
tion.
Herbaceous plants are best treated by root immersion in the laboratory or green-
house; however, remission only lasts a few weeks.
Safety of use is an important consideration. Both the applicators and the con-
sumers ofthe treated plants must be protected from undue exposure to clinically im-
portantantibiotics. Additionally, exposureofcommon microflorashould beavoided
to limit the selection ofpossible resistant strains. Each potential use ofantibiotic for
control ofaplant disease should be carefully evaluated, not only for efficacyagainst
the disease, but for safety as well.
T.A. Chen said that anti-spiroplasma factor(s) are commonly present in plant
homogenates. The degree of inhibition on spiroplasma growth varies with different
species. The effect of plant extracts on the multiplication of spiroplasmas grown in
vitro is an almost inverse linear relationship between the concentration of plant ex-
tract in the medium and the number of spiroplasmas inoculated.
Experiments with Spiroplasma citri and corn stunt spiroplasma suggest that the
anti-spiroplasma action of plant extracts is spiroplasmastatic rather than
spiroplasmacidal. The inhibitory factor(s) may bind to the cell membrane tem-
porarily and imbalance the process of cell replication. Unlike animal homogenates,
the plant tissue extracts do not increase their inhibitory activity after prolonged
storage. At present, the exact nature of spiroplasma inhibitory factor(s) liberated
from disrupted plant tissues is still unknown.
K. Jurmanova discussed the fact that since the isolation ofmycoplasmas from cell
cultures was first described by Robinson et al. in 1956, a number of methods have
been developed in an attempt to decontaminate cell cultures from mycoplasmas, but
the desired effect has not been achieved. This problem has recently been reviewed by
Barile in 1981. The agents generally used for this purpose are antibiotics; namely,
tetracyclines, kanamycin, chloramphenicol, novobiocin, tylosine, gentamicin, clin-
damycin, and so on. Most writers recommended the use of tetracyclines, but the
crucial point with them is the choice of dose, which must be sufficiently high to
eliminate mycoplasmas, butnot too toxic tocell culture. The efficiency ofantibiotics
can be enhanced by combination with hypotonic solutions, increased cultivation
temperature (40-41°C), or specific antisera having high titers of antibody against
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the mycoplasma species contaminating the cell culture under treatment.
The treatment of mycoplasma-contaminated cell cultures poses a hazard, since
any handling of them in the laboratory increases the risk of spreading this con-
tamination to other cell cultures. Therefore the decontamination is carried out only
with very rare and unreproduceable cell cultures such as hybridoma lines used for
the production of monoclonal antibodies against human organ and membrane an-
tigens. Human line SKO-007 was decontaminated from mycoplasmas at Stanford in
1981 by exposure to 41°C for 40 hours and by treatment with a combination of
kanamycin and clindamycin.
The prerequisite of effective treatment of cell cultures is the preliminary deter-
mination ofthe sensitivity ofcontaminating mycoplasmas to the selected antibiotics.
The efficiency of the treatment becomes apparent after cultivation ofthe cell culture
for several weeks without antibiotics; the usual finding is only an abrupt fall in
mycoplasma titer while a smnall number of mycoplasmas persist further. The treat-
ment should be repeated with large doses of both antiserum and antibiotics, since
living cells afford mycoplasmas a considerable degree of protection against an-
tibiotics. Mycoplasmas in cell cultures can become resistant to all antibiotics. Theef-
fective concentration of antibiotics against mycoplasmas varies from species to
species and from strain to strain. Treatment with antibiotics may affect the cell
culture where selection of the cell population may occur and the characteristics of
the cell culture may be changed. The best method, in fact, is rapid removal ofa con-
taminated cell culture from the laboratory.
Use of mycoplasma-contaminated cell cultures for the cultivation of viruses
results in the contamination of stock viruses; various chemicals and high concen-
trations of antibiotics have been recommended, e.g., 10,000/g kanamycin or tetra-
cycline per ml of viral suspension.
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